Showing results (291-300 of 427) with videos related to
Sort By:
Pageof 43
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast CancerOtto Metzger Filho, Karla Ballman, Jordan Campbell, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
The 6q22.33 locus and breast cancer susceptibilityTomas Kirchhoff, Zhang-qun Chen, Bert Gold, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang, Gabriella M D'Andrea, Mary E Moynahan, et al.Breast Cancer Research and Treatment|August 30, 2008
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinomaSteven Sugarman, Carolyn Wasserheit, Elizabeth Hodgman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623Halle C F Moore, Stephanie J Green, Julie R Gralow, et al.Cancer|January 23, 2014
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongueNeil M Iyengar, Amit Kochhar, Patrick G Morris, et al.Nature Genetics|November 5, 2013
ESR1 ligand-binding domain mutations in hormone-resistant breast cancerWeiyi Toy, Yang Shen, Helen Won, et al.Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.Pageof 43